Article Details
Retrieved on: 2024-09-19 13:46:26
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the extensive pipeline of biopharmaceutical drugs being developed for Crohn's disease, highlighting emerging treatments such as monoclonal antibodies and S1P receptor modulators. Companies like Arena Pharmaceuticals, Celgene, and AstraZeneca are key players involved.
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here